Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. 2024-02-13 03:26
BioVaxys Announces Successful Test-Run Production of its Bi-Haptenized Ovarian Cancer Vaccine 2022-12-01 21:00
BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021 2022-11-16 21:00
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development 2022-06-15 20:00
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement 2022-05-18 20:00
BioVaxys Expands Cancer Vaccine Platform 2022-03-30 16:02
BioVaxys Announces Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program in Collaboration with The Ohio State University 2022-03-17 20:18
BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein 2022-02-16 21:00
BioVaxys Further Expands Intellectual Property Portfolio in Global Markets 2021-10-28 20:00
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine 2021-10-20 21:24
BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission 2021-09-28 20:00
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins 2021-09-23 15:00
BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone 2021-09-17 15:00
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs 2021-09-14 15:00
Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration 2021-09-07 20:00
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans 2021-08-03 20:00
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH 2021-07-22 21:50
BioVaxys Announces Non-Brokered Private Placement 2021-06-29 10:46
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development 2021-06-15 04:19
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study 2021-06-01 20:00
1 2